biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > and i am sure chrispi will find this to be very positive

<< Previous

Bullboard Posts

Next >>

Comment by LOOPA441on Jun 21, 2022 7:56am

160 Views

Post# 34770610

RE:RE:and i am sure chrispi will find this to be very positive

What do you think the plan is for the XB3 assets?

Based on the pipeline presented, the entire platform looks like it was put on the back burner.

Understand the need/value in getting our valuation up, but is Bioasis still "The Blood Brain Barrier Company"?

And where are Oxyrane and Aposense...

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages